Skip to main content
Home
Articles
Latest Issue
Issue Archive
Special Issues
Supplements
Categories
Conference Correspondent
ASH 2023 - CLL
SABCS 2023 - HR+/HER2- MBC
Web Exclusives
All Web Exclusives
Interview with the Innovators
Rapid Reactions
FDA Oncology Update
Videos
Press Releases
Gastrointestinal Cancer Monthly Minutes
For Authors
Author Guidelines
Symptom Management Overview
Letters to the Editor/Perspectives
Join Our Peer Review
Submit a Manuscript
About
About JHOP
Contact Us
Editorial Policies
Peer-Review Process
About the Editors
Editorial Board
Editorial Process
Advertising Policy
Advertise
Subscribe
Home
Articles
Latest Issue
Issue Archive
Special Issues
Supplements
Categories
Conference Correspondent
ASH 2023 - CLL
SABCS 2023 - HR+/HER2- MBC
Web Exclusives
All Web Exclusives
Interview with the Innovators
Rapid Reactions
FDA Oncology Update
Videos
Press Releases
Gastrointestinal Cancer Monthly Minutes
For Authors
Author Guidelines
Symptom Management Overview
Letters to the Editor/Perspectives
Join Our Peer Review
Submit a Manuscript
About
About JHOP
Contact Us
Editorial Policies
Peer-Review Process
About the Editors
Editorial Board
Editorial Process
Advertising Policy
Advertise
Editorial
,
Biosimilars
Adoption of Biosimilars—Why the Delay?
Scott A. Soefje, PharmD, MBA, BCOP, FCCP, FHOPA
Read More
Meeting Highlights
Biosimilars
,
Oncology Pharmacy Programs
,
ASCO Highlights
Pharmacist-Driven Intervention Significantly Increases Biosimilar Adoption in Clinical Practice
Read More
Original Article
,
Biosimilars
,
Transplant
Comparing Single-Center Outcomes Between Reference and Biosimilar Granulocyte Colony-Stimulating Factor Drugs Used for Autologous Stem-Cell Mobilization
Trace Bartels, PharmD; Molly Klanderman, PhD, MS; Jaime Rogers, MSN, RN; Kristin Gray, MSN, RN; Heidi Kosiorek, MS; Chris Coughlin, PharmD, BCOP
Read More
Meeting Highlights
Biosimilars
,
ASCO Highlights
Oncologists’ Common Misconceptions About Biosimilars Revealed in a Recent Survey
Read More
Biosimilars
Comparative Efficacy and Safety of the Bevacizumab Biosimilar MIL60 versus Bevacizumab Reference in Patients with Advanced or Recurrent Nonsquamous NSCLC
Read More
Biosimilars
Same-Day Pegfilgrastim or PFG-cbqv Prophylaxis of Chemotherapy-Induced Neutropenia in Bendamustine plus Rituximab and CHOP±R Regimens in Patients with Lymphoma and CLL
Read More
Biosimilars
Same-Day Pegfilgrastim or Pegfilgrastim-cbqv Prophylaxis in miniCHOP Chemotherapy-Based Regimens for Non-Hodgkin Lymphoma
Read More
Biosimilars
Demographics and Clinical Characteristics of Patients with Metastatic Colorectal Cancer Treated with Bevacizumab-awwb in Real-World Oncology Clinics
Read More
Biosimilars
Impact of the Oncology Care Model on Use of Bone Supportive Medications, Antiemetics, and Growth Factors
Read More
Biosimilars
Cost-Efficiency Analysis of Conversion from Pegfilgrastim with On-Body Injector to Pegfilgrastim-jmdb to Provide Budget-Neutral Expanded Access to Prophylaxis and Treatment
Read More
1
2
3
4
Page 1 of 7
Results 1 - 10 of 65